Pieris Pharmaceuticals, Inc. Stock price
Equities
PIRS
US7207951036
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.185 USD | -4.49% | -7.75% | +1.32% |
Mar. 27 | North American Morning Briefing : Stocks Edge -2- | DJ |
Jan. 05 | Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief | MT |
Financials (USD)
Sales 2023 * | 31.98M | Sales 2024 * | 6.62M | Capitalization | 19.15M |
---|---|---|---|---|---|
Net income 2023 * | -28M | Net income 2024 * | -17M | EV / Sales 2023 * | 0.6 x |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 2.89 x |
P/E ratio 2023 * |
-0.55
x | P/E ratio 2024 * |
-0.97
x | Employees | 136 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 92.55% |
Latest transcript on Pieris Pharmaceuticals, Inc.
1 day | +3.03% | ||
1 week | -7.76% | ||
Current month | +17.32% | ||
1 month | +20.61% | ||
3 months | +5.33% | ||
6 months | -34.87% | ||
Current year | +6.43% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Yoder
CEO | Chief Executive Officer | 48 | 09-12-31 |
Thomas Bures
DFI | Director of Finance/CFO | 49 | 17-11-30 |
Kayti Aviano
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 59 | 16-09-19 | |
James Geraghty
CHM | Chairman | 70 | 17-05-21 |
Michael Richman
BRD | Director/Board Member | 63 | 14-12-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.187 | -3.46% | 356 077 |
24-03-27 | 0.1937 | +3.03% | 1,238,321 |
24-03-26 | 0.188 | +3.47% | 358,787 |
24-03-25 | 0.1817 | -9.15% | 2,968,260 |
24-03-22 | 0.2 | +0.05% | 735,308 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.43% | 19.15M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.74% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |